NCIC CTG IND.181: Phase i study of AT9283 given as a weekly 24 hour infusion in advanced malignancies

Investigational New Drugs

Volumn 31, Issue 6, 2013, Pages 1522-1529

  Dent, S F ^a   Gelmon, K A ^b   Chi, K N ^b   Jonker, D J ^a   Wainman, N ^c   Capier, C A ^b   Chen, E X ^d   Lyons, J F ^e   Seymour, L ^c  

^a UNIVERSITY OF OTTAWA   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c QUEEN S UNIVERSITY   (Canada)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e ASTEX PHARMACEUTICALS   (United Kingdom)

Author keywords

Advanced; AT9283; Malignancies; Phase I; Recommended phase II dose

Indexed keywords

1 CYCLOPROPYL 3 [3 (5 MORPHOLINOMETHYL 1H BENZIMIDAZOL 2 YL) 1H PYRAZOL 4 YL]UREA;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ANUS CANCER; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; COLON CANCER; CONTINUOUS INFUSION; DIARRHEA; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GALLBLADDER CANCER; GASTRITIS; GYNECOLOGIC CANCER; HUMAN; HYPERTENSION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MELANOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; NONHODGKIN LYMPHOMA; PAIN; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SARCOMA; SEPSIS; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; TUMOR PAIN; UROGENITAL TRACT CANCER; VOMITING; WOUND INFECTION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BENZIMIDAZOLES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HISTONES; HUMANS; INFUSIONS, INTRAVENOUS; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASMS; PROLIFERATING CELL NUCLEAR ANTIGEN; PROTEIN KINASE INHIBITORS; SKIN; TUMOR SUPPRESSOR PROTEIN P53; UREA;

EID: 84888620601     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-013-0018-9     Document Type: Article

References (29)

1. Adams RR, Carmena M, Earnshaw WC (2001) Chromosomal passengers and the (aurora) ABCs of mitosis. Trends Cell Biol 11:49-54
2. Carmena M, Earnshaw WC (2003) The cellular geography of aurora kinases. Nat Rev Mol Cell Biol 4:842-854
3. Nigg EA (2001) Mitotic kinases as regulators of cell division and its checkpoints. Nat Rev Mol Cell Biol 2:21-32
4. Moore AS, Blagg J, Linardopoulos S, Pearson AD (2010) Aurora kinase inhibitors: novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemias. Leukemia 24:671-678
5. Qi W, Liu X, Cooke LS, Persky DO, Miller TP, Squires M et al (2012) AT9283, a novel aurora kinase inhibitor, suppresses tumour growth in aggressive B-cell lymphomas. Int J Cancer 130(12):2997-3005
6. Nadler Y, Camp RL, Schwartz C, Rimm DL, Kluger HM, Kluger Y (2008) Expression of Aurora A (but not Aurora B) is predictive of survival in breast cancer. Clin Cancer Res 14(14):4455-4462
7. Landen CN Jr, Lin YG, Immaneni A, Deavers MT, Merritt WM, Spannuth WA et al (2007) Overexpression of the centrosomal protein Aurora-A kinase is associated with poor prognosis in epithelial ovarian cancer patients. Clin Cancer Res 13(14):4098-4104
8. Bischoff JR, Anderson L, Zhu Y, Mossie K, Ng L, Souza B et al (1998) A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J 17(11):3052-3065
9. Renshaw JS, Patnaik A, Gordon M, Beeram M, Fischer A, Gianella-Borradori A et al (2007) A phase I two arm trial of AS703569 (R763), an orally available aurora kinase inhibitor, in subjects with solid tumors; preliminary results. J Clin Oncol 25(suppl):622s, abstract 14130
10. Gritsko TM, Coppola D, Paciga JE, Yang L, Sun M, Shelley SA et al (2003) Activation and overexpression of centrosome kinase BTAK/Aurora-A in human ovarian cancer. Clin Cancer Res 9(4):1420-1426
11. Katayama H, Ota T, Jisaki F, Ueda Y, Tanaka T, Odashima S et al (1999) Mitotic kinase expression and colorectal cancer progression. J Natl Cancer Inst 91(13):1160-1162
12. Li D, Zhu J, Firozi PF, Abbruzzese JL, Evans DB, Cleary K et al (2003) Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human pancreatic cancer. Clin Cancer Res 9(3):991-997
13. Miyoshi Y, Iwao K, Egawa C, Noguchi S (2001) Association of centrosomal kinase STK15/BTAK mRNA expression with chromosomal instability in human breast cancers. Int J Cancer 92(3):370-373
14. Sakakura C, Hagiwara A, Yasuoka R, Fujita Y, Nakanishi M, Masuda K et al (2001) Tumour-amplified kinase BTAK is amplified and overexpressed in gastric cancers with possible involvement in aneuploid formation. Br J Cancer 84(6):824-831
15. Sen S, Zhou H, Zhang RD, Yoon DS, Vakar-Lopez F, Ito S et al (2002) Amplification/overexpression of a mitotic kinase gene in human bladder cancer. J Natl Cancer Inst 94(17):1320-1329
16. Howard S, Berdini V, Boulstridge JA, Carr MG, Cross DM, Curry J et al (2009) Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multi-targeted kinase inhibitor with potent Aurora kinase activity. J Med Chem 52(2):379-388
17. Curry J, Angove H, Fazal L, Lyons J, Reule M, Thompson N et al (2009) Aurora B kinase inhibition in mitosis: strategies for optimising the use of Aurora kinase inhibitors such as AT9283. Cell Cycle 8(12):1921-1929
18. Santo L, Hideshima T, Nelson EA et al (2009) AT9283, a small molecule multi-targeted kinase inhibitor induces antimyeloma activity via potent aurora kinase and STAT3 inhibition [abstract]. In: American Society Haematology Annual Meeting and Exposition, December 5-8, 2009, New Orleans, USA. Abstract 3883, Poster III-769
19. Plummer ER, Calvert H, Arkenau H, Mallett KH, Squires M, Smith D et al (2008) A dose-escalation and pharmacodynamic study of AT9283 in patients with refractory solid tumours. J Clin Oncol 26(May 20 Suppl): 117s abstract 2520
20. Foran JM, Ravandi F, O'Brien SM, Borthakur G, Rios M, Boone P et al (2008) Phase I and pharmacodynamic trial of AT9283, an aurora kinase inhibitor in patients with refractory leukemia. J Clin Oncol 27(155 Suppl):15s abstract 2566
21. Kristeleit R, Calvert H, Arkenau H, Olmos D, Adam J, Plummer ER et al (2009) A phase I study of AT9283, an aurora kinase inhibitor, in patients with refractory solid tumours. J Clin Oncol 27(Suppl 15s): abstract 2566
22. Arkenau HT, Plummer R, Molife LR, Olmos D, Yap TA, Squires M et al (2012) A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies. Ann Oncol 23(5):1307-1313
23. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al (2000) New guidelines to evaluate the response to treatment in solid tumours. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205-216
24. Walsby E, Walsh V, Pepper C, Burnett A, Mills K (2008) Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts. Haematologica 93(5):662-669
25. Linden MD, Torres FX, Kubus J, Zarbo RJ (1992) Clinical application of morphological and immunocytochemical assessments of cell proliferation. Am J Clin Pathol 97(5 Suppl 1):S4-S13
26. Cuevas E, Jones D, Wright D (1993) Immunohistological detection of tumour growth fraction (Ki-67 antigen) in formalin-fixed and routinely processed tissues. J Pathol 169(4):477-478
27. Dees EC, Infante JR, Cohen RB, O'Neil BH, Jones S, von Mehren M et al (2011) Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumours. Cancer Chemother Pharmacol 67(4):945-954
28. Macarulla T, Cervantes A, Elez E, Rodriguez-Braun E, Baselga J, Rosello S et al (2010) Phase I study of the selective Aurora A Kinase Inhibitor MLN8054 in patients with advanced solid tumours: safety, pharmacokinetics, and pharmacodynamics. Mol Cancer Ther 9(10):2844-2852
29. Shi Y, Reiman T, Li W, Maxwell CA, Sen S, Pilarski L et al (2007) Targeting aurora kinases as therapy in multiple myeloma. Blood 109(9):3915-3921